Influence of Dietary Compounds on Arsenic Metabolism and Toxicity. Part II—Human Studies

Monika Sijko * and Lucyna Kozłowska *

Department of Dietetics, Institute of Human Nutrition Sciences, Warsaw University of Life Sciences (SGGW-WULS), 159c Nowoursynowska Street, 02-776 Warsaw, Poland
* Correspondence: monika_sijko1@sggw.edu.pl (M.S.); lucyna_kozlowska@sggw.edu.pl (L.K.); Tel.: +48-22-59-370-23 (M.S.); +48-22-59-370-17 (L.K.)

Abstract: Exposure to various forms of arsenic (As), the source of which may be environmental as well as occupational exposure, is associated with many adverse health effects. Therefore, methods to reduce the adverse effects of As on the human body are being sought. Research in this area focuses, among other topics, on the dietary compounds that are involved in the metabolism of this element. Therefore, the aim of this review was to analyze the influence of methionine, betaine, choline, folic acid, vitamin B2, B6, B12 and zinc on the efficiency of inorganic As (iAs) metabolism and the reduction in the severity of the whole spectrum of disorders related to As exposure. In this review, which included 62 original papers (human studies) we present the current knowledge in the area. In human studies, these compounds (methionine, choline, folic acid, vitamin B2, B6, B12 and zinc) may increase iAs metabolism and reduce toxicity, whereas their deficiency may impair iAs metabolism and increase As toxicity. Taking into account the results of studies conducted in populations exposed to As, it is reasonable to carry out prophylactic activities. In particular nutritional education seems to be important and should be focused on informing people that an adequate intake of those dietary compounds potentially has a modulating effect on iAs metabolism, thus, reducing its adverse effects on the body.

Keywords: vitamins; minerals; inorganic arsenic; exposure; detoxification; metal toxicity; methylation

1. Introduction

Exposure to arsenic (As) affects people living in many regions of the world. This problem occurs not only in less affluent areas (such as Chile, Argentina, Bangladesh, and Mexico), but also in several hotspot regions of Europe (Poland, Hungary, Serbia, Romania, Czech Republic, Croatia, Finland, Greece, and Italy) [1]. The source of exposure to different chemical forms of As can be both environmental and occupational. Environmental pollution can be of natural origin (rocks, soils, and volcanoes, among others) and can be caused by human activities (e.g., mining, burning fossil fuels, residues of agricultural chemicals in the soil and groundwater) [2,3]. Environmental sources also include water and food contamination. The As content in food products varies and depends on the type of product and its origin. Foods that contribute most to general population exposure to inorganic arsenic (iAs) include rice and rice-based products, grains and grain-based processed products, and drinking water [4]. The second source of As exposure is occupational exposure. As is used in many industries (agriculture; horticulture; mining; wood preservation; and production of, e.g., ammunition, glass, semiconductors, dyes) [2,3].

Both environmental and occupational exposures include exposure to inorganic as well as organic forms. Inorganic forms (such as As trioxide, As pentoxide, arsenous acid, and arsenic acid) are more toxic than organic forms (monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA), arslenobetaine). Among iAs, As on the third and fifth oxidation state is the most toxic, with forms of the third oxidation state being more toxic [5–7].
Exposure to As can cause many adverse health effects. iAs has been classified as a carcinogenic compound [8]. Epidemiological studies in individuals exposed to As have shown an increased incidence of cancers including lung, kidney, liver, bladder, and skin cancers [9,10]. Long-term exposure to As in adults increased the risk of type 2 diabetes [11,12] and the risk of developing peripheral vascular disease [13], increased the incidence of skin lesions [14], and impaired lung function [15]. Furthermore, As exposure in children had a negative impact on cognitive abilities and induced neurological disorders [16,17].

The large number of people exposed to As and the many negative health effects caused by this exposure warrant, among other investigations, a deep analysis of the spectrum of health effects associated with As exposure and a search for ways that could reduce these adverse effects on the human body. Research in this area has focused, among other topics, on dietary compounds. There is no systematic summary of the results of human studies that have analyzed the effects of key dietary compounds on iAs metabolism and reduction in adverse effects caused by As exposure. Therefore, in this paper, we analyzed the results of studies in which the influence of methionine, choline, betaine, folic acid as donors of methyl groups and vitamins B_2, B_6, B_12 and zinc as reaction cofactors in the aspect of efficiency of the metabolism process as well as reduction in the severity of the whole spectrum of disorders related to As exposure.

2. Methods

In this review, the electronic database PubMed was used. The following keywords were used to search for articles: arsenic and: methionine, betaine, choline, folic acid, folate, zinc, vitamin B, vitamin B_2, vitamin B_6, vitamin B_12, riboflavin, pyridoxine, cobalamin. The review was based on the PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration [18]. The search resulted in 2434 articles, excluding those unrelated to the topic of the study and those that examined the effects of complex plant extracts. Sixty-two (4 in vitro studies and 58 human studies) original peer-reviewed articles in English were included in the analysis, which studied the effects of methionine, betaine, choline, folic acid, vitamin B_2, B_6, B_12, zinc on iAs metabolism and As-induced toxicity. Articles published between 1980 and 2020 were used, 95.2% of which were published after 2000.

3. Results

3.1. Folic Acid and Zinc as Modulators of iAs Metabolism and Toxicity—In Vitro Studies

The protective effect of folic acid (two studies) and zinc (two studies) has been analyzed in four studies on cell lines that were exposed to iAs. The results are summarized in Table 1.

3.1.1. Folic Acid—iAs Metabolism

The association between folic acid and iAs metabolism was analyzed only in one in vitro study. In a study performed in Chang human hepatocytes, folate deficiency decreased the levels of methylated arsenicals, and supplementation with folic acid showing no effects on iAs metabolism [19].

3.1.2. Folic Acid and Zinc—Toxicity of iAs

In one of the in vitro studies in Chang human hepatocyte folate supplementation decreased apoptosis, lipid peroxidation, and oxidative stress. Furthermore, folate deficiency enhanced the adverse effect of iAs, resulting in, inter alia, increased apoptosis, lipid peroxidation, and oxidative stress [19].
Table 1. Results of in vitro studies with iAs exposure and folic acid or zinc treatment.

| Reference         | Research Model                  | Study Description                                                                 | Main Results                                                                 |
|-------------------|---------------------------------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Xu et al., 2010   | Chang human hepatocytes         | CG—normal folate medium 2.3 µM (1 h) and sodium arsenite 20 µM (for 24 h)         | G1 vs. CG intracellular tAs++, methylated arsenicals↓, viability↓, early apoptosis↑, caspase-3 cleavage↑, PARP cleavage↑, percentage of cells with collapsed mitochondrial membrane potential↑, ROS↑, TBARS↓, GSH↓, CAT↓, SOD→ cytochrome c: in mitochondria↓, in cytosol↑ |
|                   |                                 | G1—folate-deficient medium (1 h) and sodium arsenite 20 µM (for 24 h)             |                                                                                |
|                   |                                 | G2—folate-supplemented medium 10 µM (1 h) and sodium arsenite 20 µM (for 24 h)    |                                                                                |
| Ma et al., 2015   | HEK293ET cells (human embryonic | CG—sodium arsenite 5 mM                                                          | G1 vs. CG cell viability↑, mRNA level of GDF1↑, ROS↓, expression of p66Shc↓    |
|                   | kidney 293 cells)               | G1—folic acid 100 µM and sodium arsenite 5 mM                                     |                                                                                |
|                   |                                 | CG—zinc sulfate 4 µM (for 4 weeks) and after that sodium arsenite 10 µM (for 24 h) | G1 vs. CG Zn total and intracellular↓, ROS↑                                  |
|                   |                                 | G1—zinc sulfate 0 µM (for 4 weeks) and after that sodium arsenite 10 µM (for 24 h) |                                                                                |
| Wong et al.,      | THP-1 (human monocytic cell     | CG—zinc sulfate 4 µM (for 4 weeks) and after that sodium arsenite 10 µM (for 4 h) | G1 vs. CG HO-1↑, SOD↓, CAT↓                                                 |
| 2019 [21]         | line)                          | G1—zinc sulfate 0 µM (for 4 weeks) and after that sodium arsenite 10 µM (for 4 h) |                                                                                |
|                   |                                 | CG—zinc sulfate 4 µM (for 4 weeks) and after that sodium arsenite 1 µM (for 4 h)  | G1 vs. CG intracellular zinc↓, transcript levels of: ICAM1↑, IL6↑, CXCL8↑     |
|                   |                                 | G1—zinc sulfate 0 µM (for 4 weeks) and after that sodium arsenite 1 µM (for 4 h)  |                                                                                |
| Sun et al., 2014  | HaCaT cells (human keratinocyte| CG—sodium arsenite 2 µM (for 24 h)                                              | G1 vs. CG zinc content in PARP-1↑, PARP-1 activity↑                           |
| [22]              | cell line)                      | G1—zinc chloride 2 µM (for 24 h) and sodium arsenite 2 µM (for 24 h)              |                                                                                |

↑—significant increase; ↓—significant decrease; ↔—no significant changes; CAT—catalase; CG—control group; CXCL8—C-X-C motif chemokine ligand 8; G1—group 1; GDF 1—growth differentiation factor 1; GSH—glutathione; HO-1—heme oxygenase-1; ICAM1—intercellular adhesion molecule 1; IL-6—Interleukin 6; PARP—poly(ADP) polymerase; PARP-1—poly(ADP) polymerase-1; ROS—reactive oxygen species; SOD—superoxide dismutase; tAs—total arsenic species; TBARS—thiobarbituric acid reactive substances.
In the in vitro study performed on human embryonic kidney 293 cells, folic acid showed a protective effect against adverse effect of iAs by increasing the viability of cells and decrease the oxidative stress levels through decreasing the levels of reactive oxygen species and p66Shc expression [20].

Furthermore, a study with a human monocyte cell line, carried out in the presence of iAs, demonstrated that zinc deficiency increased oxidative stress (increased reactive oxygen species production) and inflammatory response (inter alia, through increased production of inflammatory markers) [21].

In the human keratinocyte cell lines exposed to iAs, zinc reduced DNA damage by affecting the production of poly(ADP-ribose) polymerase-1 (increased content zinc in this protein and its activity; decreased As binding with this protein) [22].

### 3.1.3. Folic Acid and Zinc—Summary

In vitro studies have shown that folic acid deficiency decreased iAs metabolism and supplementation had no influence. Folic acid deficiency (1 h) could exacerbate the adverse effect of exposure to iAs in a short period of time, and the addition of folic acid (also only for 1 h) did not improve iAs metabolism; in both cases, a long exposure time to iAs (24 h) was used.

However, these compounds reduced the adverse changes induced by iAs in three cell lines, mainly through decreased apoptosis, oxidative stress and DNA damage. Although the studies were carried out on different cell lines and different doses of folic acid (10, 100 µM) zinc (2 µM) and iAs (2, 20 µM; 5 mM) with the same exposure times iAs (24 h), favorable results were obtained.

In two in vitro studies with iAs exposure (for 4 or 24 h), folic acid and zinc deficiency intensified oxidative stress, apoptosis and inflammation. In these cases, both short folic acid deficiency (1 h) and long zinc deficiency (4 weeks) had an adverse effect.

### 3.2. Relationship between Dietary Intake of Selected Compounds and iAs Metabolism and Toxicity

Twenty-two studies in subjects exposed to iAs (mainly in drinking water) analyzed the relationships between the intake of a whole range of nutrients and iAs metabolism as well as toxicity (Table 2).

#### 3.2.1. Nutrient Intake—iAs Metabolism

The main results of studies that analyzed the relationships between intakes of methionine, betaine, choline, vitamins B2, B6, B12, folate, zinc and biomarkers of iAs metabolism in children and then in adults are presented below.

The relationship between nutrient intake and iAs metabolism was reported in four studies conducted with children.

In the case of vitamin B2, no significant relationship was observed between its intake and the urinary excretion of As metabolites (%MMA, %DMA, and %iAs) [23]. A negative association between vitamin B6 intake and %MMA in urine was observed only in one study involving children, and there were no significant relationships between vitamin B6 intake and the percentage of DMA and iAs in the urine [23]. In contrast, in the study by Kurzius-Spencer et al. [24], no significant association was observed between vitamin B6 intake and the urinary excretion of iAs metabolites. Three studies showed no relationship between vitamin B12 intake and iAs metabolism in children [23–25]. Folate intake was negatively associated with urinary %MMA [25,26] and, additionally, in one of these studies, a positive association with urinary %DMA was observed [26]. In these studies, no association was observed between intake of folic acid and %iAs, tAs in the urine [25,26] and urinary excretion of iAs metabolites [24].

The relationship between nutrient intake and iAs metabolism was also analyzed in the adult population (10 studies).

In the study by Heck et al. [27], methionine intake (in groups of men and women) was positively associated with urinary %MMA, whereas no such relationship was observed in
another study involving women [28]. In the study by Heck et al. [28], methionine intake also was positively associated with urinary %DMA [28], but in a subsequent study by these authors, this relationship was not significant [27]. Additionally, these two studies showed a negative association between methionine intake and %iAs in the urine [27,28]. Moreover, in the study by Heck et al. [29], a higher methionine intake was associated with an increased excretion of tAs in the urine. Another analyzed ingredient was betaine; there was no relationship between betaine intake and iAs metabolism [27,28].

Regarding choline, two studies showed intake of this compound was not associated with urinary %MMA, but a positive association was observed with the DMA/MMA ratio [27,28]. In contrast, one study demonstrated associations with the other iAs metabolites in urine (positive association of choline intake with %DMA and negative association with %iAs) [28].

The relationships between vitamin B\textsubscript{2} intake and iAs metabolism have been analyzed in several studies. One study showed a positive association between vitamin B\textsubscript{2} intake and urinary %MMA [27], while another study showed a negative association with this form [30]. Additionally, in several studies, there were no relationships [28,31–33]. In the study by Spratlen et al. [30], vitamin B\textsubscript{2} intake was positively related with urinary %DMA, while no such relationship was shown in other studies [27,28,31–33]. In contrast, a negative association with %iAs was shown in the study by Spratlen et al. [30], while no such relationship was observed in other studies [27,28,31–33]. There was no significant relationship between vitamin B\textsubscript{2} intake and urinary excretion of tAs [34]. One study revealed a positive association between vitamin B\textsubscript{2} intake and first methylation step (MMA/iAs), and negative with the second methylation step (DMA/MMA) [27].

The relationship between vitamin B\textsubscript{6} intake and iAs metabolism was analyzed in seven studies. In the study by Spratlen et al. [30], vitamin B\textsubscript{6} intake was negatively associated with urinary %MMA and positively with %DMA. In the study by Kurzius-Spencer et al. [24], these relationships were not significant. Both studies showed a negative association with urinary %iAs [24,30], while the study by Argos et al. [34] showed a positive association with tAs in the urine. On the other hand, in several studies, there was no relationship between vitamin B\textsubscript{6} intake and urinary %iAs metabolite excretion [27,28,31,33].

Vitamin B\textsubscript{12} intake correlated positively with urinary %MMA in the study by Heck et al. [27]; other studies did not show such a relationship [24,28,30,32]. The study by Lopez-Carillo et al. [28] also showed a positive association with urinary %DMA, which was not observed in the studies of other authors [27,30,32]. Only in two studies, the intake of this vitamin was negatively associated with %iAs in the urine [27,28]. This relationship was not confirmed in other studies [24,30,32]. Positive associations with ratios of various forms of As in the urine were also observed in studies by Heck et al. [27] and Lopez-Carillo et al. [28]. However, the intake of this vitamin did not affect the urinary excretion of tAs [34].

None of the studies observed a relationship between folic acid intake and urinary %MMA and %DMA [27,28,30–33]. In contrast, the study by Howe et al. [35] showed that intake of sum of vitamins B\textsubscript{2}, B\textsubscript{6}, B\textsubscript{12} and folate had a negative association with the proportion of monomethyl arsenic species. In turn, folate intake was negatively associated with urinary %iAs in one study [28], which was not shown in other studies [27,30–33]. Folate intake was positively associated with ratio DMA/iAs [28]. No relationship between folate intake and tAs in the urine was reported in the study by Argos et al. [34].

Associations between zinc intake and iAs metabolism were demonstrated in two studies. They included one negative association with urinary %MMA and a positive association with urinary %DMA [28,33]. Moreover, the study by Lopez-Carillo et al. [28] demonstrated a negative association with urinary %iAs and a positive association with ratios DMA/MMA and DMA/iAs.
3.2.2. Nutrient Intake—Toxicity of As

Several studies have analyzed the relationship between nutrient intake and the severity of adverse changes in the body and the risk of developing diseases associated with exposure to As.

In one study involving adults and children, an adverse effect of high vitamin B$_6$ intake was observed; it was associated with an increased risk of diabetes and metabolic syndrome [31]. On the other hand, in another study, a low intake of vitamin B$_2$, B$_6$, B$_{12}$ and folic acid in subjects exposed to iAs with drinking water was associated with worse cardiovascular outcomes (through increased pulse pressure and marginally systolic hypertension) [36]. A protective effect of nutrients was demonstrated in one study, in which a reduction in the severity of oxidative stress (reduced urinary 15-F$_{2t}$-isoprostane) was observed in adults who had a higher intake of B vitamins [35].

However, no consistent effect was observed between folic acid intake and bladder cancer risk in adults [37]. Three studies demonstrated an increased risk of skin lesions in individuals who had low intakes of choline, vitamin B$_2$, folate and zinc [38–40]. In turn, a reduced risk of As-related skin lesions was observed in adults who consumed higher amounts of vitamin B$_2$, B$_6$ and folic acid [41].

Low folic acid intake was not associated with cognitive performance in children, but higher intake was positively associated with cognitive abilities. In this study, moreover, several relationships were observed between tAs in the urine and cognitive performance depending on the level of folic acid intake, but it was an inconsistent effect [42]. In another study by the same author, there was no relationship between urinary tAs and achievement (broad math and reading scores) among children and B vitamin intake [43].

In turn, negative associations between vitamin B$_{12}$ intake and tAs concentrations in toenails were observed in the study by Gruber et al. [44].

3.2.3. Nutrient Intake—Summary

The results of human studies on the relationship between nutrient intake and iAs metabolism are inconclusive. They indicate that some nutrient intake may contribute to iAs elimination from the body. In several studies, the intake of such nutrients as methionine, choline, vitamin B$_2$, vitamin B$_6$, B$_{12}$, folate, zinc was observed to be correlated with iAs metabolism. However, some of the correlations between nutrient intakes (betaine, choline, vitamin B$_2$, vitamin B$_6$, vitamin B$_{12}$, and folate) and the urinary content of various forms of iAs suggest that these nutrients may or may not impair iAs metabolism.

The authors also observed a relationship between a high intake of B vitamins and folic acid and a reduction in the adverse changes associated with exposure to iAs (decreased oxidative stress, reduced risk of As-related skin lesions, and increased cognitive abilities). In turn, low intake (choline, B vitamins, folic acid, and zinc) was associated with the deterioration of cardiovascular outcomes and an increased risk of skin lesions. The differences in these results may be due to the levels of nutrient intake (higher intake was connected with a reduction in the negative effects associated with iAs exposure, while a low intake may exacerbate these effects).

However, in several studies, there are conflicting data that require clarification. No consistent effect was observed between B vitamins and folic acid intake, and risk of diabetes and bladder cancer, as well as cognitive performance and achievements in children. In these studies, the author suggested that the lack of, or unclear, effect may be due to the low variability in vitamin intake, or that intake was above a sufficient level in the majority of participants. Additionally, the results could also be influenced by additional metabolic differences (e.g., genetic variation or differences in iAs metabolism—the study was conducted on children, adults and patients with bladder cancer). In one of these studies, a high intake of vitamin B$_6$ was associated with diabetes-related outcomes, but this effect was unclear because, in most studies, low consumption contributed to the severity of the negative effects and, therefore, this aspect requires further analysis.
Table 2. Relationship between dietary compound intake and iAs metabolism and health effects related to As exposure.

| Reference                  | Population                          | Dietary Assessment Methods | Component                           | Main Results                                                                 |
|----------------------------|-------------------------------------|---------------------------|-------------------------------------|------------------------------------------------------------------------------|
| Desai et al., 2020 [23]    | Montevideo (Uruguay), children ~7 years $n=290$ | 2 nonconsecutive 24 h recalls | vitamin $B_6$—dietary intake        | urine: %DMA (NS), %MMA (−), %iAs (NS)                                         |
|                            |                                     |                           | vitamin $B_2$ and $B_{12}$—dietary intake | urine: %DMA (NS), %MMA (NS), %iAs (NS)                                         |
| Desai et al., 2020 [25]    | Montevideo (Uruguay), children ~7 years $n=307$ | 2 nonconsecutive 24 h recalls | vitamin $B_{12}$—dietary intake     | urine: %DMA (NS), %MMA (NS), %iAs (NS)                                         |
|                            |                                     |                           | folate—dietary intake               | urine: %DMA (NS), %MMA (−), %iAs (NS)                                         |
| Kordas et al., 2016 [26]   | Montevideo (Uruguay), children ~5–8 years $n=357$ | 2 nonconsecutive 24 h recalls | folate—dietary intake               | urine: %DMA (+), %MMA (−), %iAs (NS), tAs (NS)                               |
| Kurzius-Spencer et al., 2017 [24] | U.S., adults and children > 6 years $n=2420$ | 24 h recall                | vitamin $B_6$—dietary intake        | urine: %DMA (NS), %MMA (NS), %iAs (NS), DMA/MMA (NS) (in the group of children) |
|                            |                                     |                           | vitamin $B_{12}$—dietary intake     | urine: %DMA (NS), %MMA (NS), %iAs (NS), DMA/MMA (NS) (in the group of adults)  |
|                            |                                     |                           | folate—dietary intake               | urine: %DMA (NS), %MMA (NS), %iAs (NS), DMA/MMA (NS) (in the group of children) |
| Spratlen et al., 2018 [31] | Arizona, Oklahoma, North Dakota, South Dakota, men and women >14 aged $n=935$ | FFQ                        | vitamin $B_2$, vitamin $B_6$, folic acid—dietary intake | urine: %DMAAs (NS), %MMAs (NS), %iAs (NS)                                    |
|                            |                                     |                           | vitamin $B_6$—dietary intake        | risk for metabolic syndrome (+), risk for diabetes (+), HOMA2-IR (+)          |
|                            |                                     |                           | vitamin $B_{12}$—dietary intake     | risk for metabolic syndrome (NS), risk for diabetes (NS), HOMA2-IR (NS)       |
|                            |                                     |                           | methionine—dietary intake           | urine: %DMA (+), %MMA (−), %iAs (−), DMA/MMA (+), DMA/DMAs (+)               |
|                            |                                     |                           | betaine—dietary intake              | urine: %DMA (NS), %MMA (NS), %iAs (−), DMA/MMA (+), DMA/DMAs (+)              |
|                            |                                     |                           | choline—dietary intake              | urine: %DMA (+), %MMA (−), %iAs (−), DMA/MMA (+), DMA/DMAs (+)               |
|                            |                                     |                           | vitamin $B_2$, vitamin $B_6$—dietary intake | urine: %DMA (NS), %MMA (NS), %iAs (−), DMA/MMA (+), DMA/DMAs (+)               |
|                            |                                     |                           | vitamin $B_{12}$—dietary intake     | urine: %DMA (NS), %MMA (NS), %iAs (−), DMA/MMA (+), DMA/DMAs (+)               |
|                            |                                     |                           | folate—dietary intake               | urine: %DMA (NS), %MMA (NS), %iAs (−), DMA/MMA (+), DMA/DMAs (+)               |
|                            |                                     |                           | zinc—dietary intake                 | urine: %DMA (NS), %MMA (NS), %iAs (−), DMA/MMA (+), DMA/DMAs (+)               |
| Lopez-Carillo et al., 2016 [28] | Mexico, women $n=1027$ | FFQ                        | methionine—dietary intake           | urine: tAs↑ and (+)                                                          |
| Heck et al., 2009 [29]     | Bangladesh, men and women $n=10,402$ | FFQ                        | methionine—dietary intake           | urine: tAs↑ and (+)                                                          |
| Reference          | Population                        | Dietary Assessment Methods | Component                        | Main Results                                                                                                                                 |
|--------------------|-----------------------------------|---------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Heck et al., 2007  | $n = 1016$ Bangladesh, men and women | FFQ                       | methionine—dietary intake        | urine: %DMA (NS), %MMA (+), %iAs (−), MMA/iAs (+), DMA/MMA (NS)                                                                             |
|                    |                                   |                           | betaine—dietary intake           | urine: %DMA (NS), %MMA (NS), %iAs (NS), MMA/iAs (NS), DMA/MMA (NS)                                                                         |
|                    |                                   |                           | choline—dietary intake           | urine: %DMA (NS), %MMA (NS), %iAs (NS), MMA/iAs (NS), DMA/MMA (+)                                                                       |
|                    |                                   |                           | vitamin B$_2$—dietary intake     | urine: %DMA (NS), %MMA (+), %iAs (NS), MMA/iAs (+), DMA/MMA (−)                                                                         |
|                    |                                   |                           | vitamin B$_6$—dietary intake     | urine: %DMA (NS), %MMA (NS), %iAs (NS), MMA/iAs (NS), DMA/MMA (NS)                                                                       |
|                    |                                   |                           | folate—dietary intake           | urine: %DMA (NS), %MMA (NS), %iAs (NS), MMA/iAs (NS), DMA/MMA (NS)                                                                       |
| Bommarito et al.,  | $n = 1166$ Chihuahua (Mexico), men and women | FFQ                       | vitamin B$_2$, vitamin B$_{12}$, folate—sufficient and insufficient | urine: %DMA**(+)**, %MMA**(+)**, %iAs**(+)**                                                                                               |
| 2019 [32]          |                                   |                           | folate—dietary intake           | urine: %DMA(−), %MMA(−), %iAs(−)                                                                                                          |
| Spratlen et al.,   | $n = 405$ Arizona, Oklahoma, North Dakota, South Dakota, men and women | FFQ                       | vitamin B$_2$, B$_6$—dietary intake | urine: %DMA(−), %MMA(−), %iAs(−)                                                                                                          |
| 2017 [30]          |                                   |                           | zinc—dietary intake             | urine: %DMA(−), %MMA(−), %iAs(−)                                                                                                          |
| Steinmaus et al.,  | $n = 87$ U.S., men and women       | HHHQ                      | vitamin B$_2$, vitamin B$_6$, folate—dietary intake | urine: %DMA(−), %MMA(−), %iAs(−)                                                                                                          |
| 2005 [33]          |                                   |                           | folate—dietary intake           | urine: %DMA(−), %MMA(−), %iAs(−)                                                                                                          |
| Argos et al.,      | $n = 9833$ Araihazar (Bangladesh), men and women | FFQ                       | vitamin B$_6$—dietary intake     | urine: tAs (+)                                                                                                                              |
| 2010 [34]          |                                   |                           | folate—dietary intake           | urine: tAs (NS)                                                                                                                             |
| Chen et al.,       | $n = 10,910$ Bangladesh, men and women | FFQ                       | vitamin B$_2$, B$_6$, B$_{12}$, folate—low intake level | ORs of high pulse pressure†, ORs of systolic hypertension† (weak association)                                                            |
| 2007 [36]          |                                   |                           | folate—dietary intake           | ORs of high pulse pressure†, ORs of systolic hypertension† (weak association)                                                            |
| Howe et al.,       | $n = 418$ New Hampshire, men and women | FFQ                       | vitamin B$_2$, vitamin B$_6$, vitamin B$_{12}$, folate—sum of B vitamin—dietary intake | urine: proportion of MAs (−), 15-F$_2$-IsoP (−)                                                                                                |
| 2017 [35]          |                                   |                           | folate—dietary intake           | ORs of high pulse pressure†, ORs of systolic hypertension† (weak association)                                                            |
| Koutros et al.,    | $n = 2366$ Maine, New Hampshire, Vermont, case with bladder cancer and control group | DHQ                       | folate—high and low intake level | ORs of risk of bladder cancer**(+)** (weak association)                                                                                   |
| 2018 [37]          |                                   |                           | folate—dietary intake           | ORs of high pulse pressure†, ORs of systolic hypertension† (weak association)                                                            |
| Melkonian et al.,  | $n = 16,391$ Araihazar (Bangladesh), cases with skin lesions and control group | FFQ                       | vitamin B$_2$, folate—low intake level | keratotic skin lesion risk (+)                                                                                                           |
| 2012 [38]          |                                   |                           | folate—dietary intake           | keratotic skin lesion risk (+)                                                                                                           |
Table 2. Cont.

| Reference            | Population                        | Dietary Assessment Methods | Component                                      | Main Results                                      |
|----------------------|-----------------------------------|----------------------------|-------------------------------------------------|--------------------------------------------------|
| Deb et al., 2012 [39]| West Bengal, cases with skin lesions and control group; $n = 208$ | 24 h recall                | choline, vitamin B$_2$, zinc—low intake level | ORs of skin lesions↑ (in the group of women)     |
|                      |                                   |                            | choline, zinc—low intake level                 | ORs of skin lesions↑                               |
|                      |                                   |                            | vitamin B$_6$, vitamin B$_{12}$, folate        | ORs of skin lesions↑ (in the group of men)        |
| Mitra et al., 2004 [40]| West Bengal (India), cases with skin lesions and control group; $n = 384$ | 24 h recall                | folate—low intake level                        | ORs of skin lesions↑                              |
|                      |                                   |                            | vitamin B$_2$, vitamin B$_6$, zinc             | ORs of skin lesions↑                               |
| Zablotska et al., 2008 [41]| 10,628 Araihaazar (Bangladesh), men and women | FFQ                        | vitamin B$_2$, folic acid—high intake level   | PORs risk for skin lesions↓                        |
|                      |                                   |                            | vitamin B$_{12}$                               | PORs risk for skin lesions↓                        |
| Desai et al., 2018 [42]| Montevideo (Uruguay), children ~5–8 years; $n = 328$ | 2 nonconsecutive 24 h recalls | folate—low intake level                        | cognitive performance (NS)                         |
|                      |                                   |                            | tAs—concept formation (−), tAs—scores of numbers reversed subtest (+), tAs—cognitive efficiency (+) |
|                      |                                   |                            | folate—mean intake level                        | scores on: verbal comprehension (+), visual auditory learning (+), verbal ability (+), general intellectual abilities (+) |
|                      |                                   |                            | tAs—sound integration scores (+)               |                                                   |
|                      |                                   |                            | folate—high intake level                        | scores on: visual auditory learning (−), concept formation (+), numbers reversed (+), cognitive efficiency (+) |
|                      |                                   |                            | tAs—concept formation (+)                      |                                                   |
| Desai et al., 2020 [43]| Montevideo (Uruguay), children ~5–8 years; $n = 239$ | 2 nonconsecutive 24 h recalls | vitamin B$_2$, vitamin B$_6$, vitamin B$_{12}$, folate—dietary intake | broad math and reading scores (calculation, math facts fluency, applied problems, sentence reading fluency, letter word identification, passage comprehension) and urinary tAs (NS) |
| Gruber et al., 2012 [44]| New Hampshire, men and women; $n = 920$ | FFQ                        | vitamin B$_{12}$—dietary intake                | toenail: tAs (−)                                  |

↑—significant increase; ↓—significant decrease; ↔—no significant changes; (+)—positively association; (−)—negatively association; (NS)—no significant association; DHQ—diet history questionnaire; DMA—dimethylarsinic acid; DMAs—monomethyl arsenic species; FFQ—food frequency questionnaire; HHHQ—health habits and history questionnaire; HOMA2-IR—Homeostatic Model Assessment Index 2; iAs—inorganic arsenic; MMA—monomethylarsonic acid; MMAs—monomethyl arsenic species; ORs—odds ratios; PORs—prevalence odds ratios; tAs—total arsenic species; 15-F$_2$-IsoP—15-F$_2$-isoprostane.
3.3. Folic Acid and Zinc Supplementation

Table 3 includes results from studies in which folic acid (eight studies) and zinc (one study) were supplemented in a population exposed to As.

3.3.1. Folic Acid and Zinc Supplementation—iAs Metabolism

Five studies analyzed the protective effect of folic acid and zinc supplementation on iAs metabolism. Changes in iAs metabolite concentrations (inter alia, decreased concentrations of MMA in the blood and increased urinary excretion of DMA) were observed in people taking folic acid supplementation [45]. In a study by Bozack et al. [46], folic acid supplementation in subjects with low and normal blood concentrations of this compound also altered iAs metabolism profile (by increased percentage dimethyl-arsenical species and decreased %iAs and monomethylarsenical species in the urine). In the study by Peters et al. [47] conducted on a Bangladeshi population, folic acid supplementation at a higher dose (800 µg/db) reduced the concentration of tAs in the blood. This effect persisted even after 12 weeks from the end of supplementation, but no such effect was observed with a lower dose of this vitamin (400 µg/db). Folic acid supplementation in participants with betaine concentrations below the median affected iAs metabolism (inter alia, through an increased percentage of dimethyl-arsenical species and decreased percentage of monomethyl arsenical species in the urine) [48]. In contrast, in a group of children, zinc supplementation decreased urinary %DMA, but did not affect the concentration of other As biomarkers in the urine [49]. In a group of Bangladeshi residents exposed to iAs in drinking water supplementation with folic acid, there was an influence on parameters related to iAs metabolism through increased plasma choline and betaine concentration and a percentage decrease in dimethylglycine in the plasma. There were no significant differences between groups receiving lower (400 µg/day) and higher (800 µg/day) doses of folic acid [50].

3.3.2. Folic Acid Supplementation—Toxicity of As

In one study, symptoms of chronic arsenic intoxication were analyzed in an adolescent girl who was taking globules (containing iAs). Treatment with thiamine and folic acid, among others, reduced the adverse symptoms and the concentration of iAs in urine and hair [51]. In contrast, folic acid supplementation did not alter post-translational histone modifications in peripheral blood mononuclear cells from Bangladeshi adults [52]. Ghose et al. [53] showed that folic acid supplementation reduced adverse symptoms in patients with chronic As toxicity.

3.3.3. Folic Acid and Zinc Supplementation—Summary

In four studies, folic acid supplementation (in doses 400 and 800 µg/day for 12 or 24 weeks) improved iAs metabolism in adults (mainly through increased urinary DMA concentration and decreased tAs concentration in the urine and the blood). In one of these studies, only a higher dose of folic acid improved iAs metabolism. In turn, zinc supplementation (30 mg/day for 6 months) in children resulted in a different effect (decreased urinary DMA concentration).

In two studies, folic acid supplementation (5 mg/day) reduced the adverse symptoms associated with As poisoning, while in one study, folic acid supplementation with a small dose (400 µg/day) had no effect on epigenetic regulation. A short period of supplementation (12 weeks) with folic acid or using a low dose of folic acid (400 mg/day) could make this effect invisible. The authors also indicate that the As-removing water filter was used during the study, which could counteract the effects caused by folic acid supplementation.
Table 3. Results of studies conducted in people with As exposure and supplementation with folic acid or zinc.

| Reference          | Research Model       | Study Description                                                                 | Main Results                                                                                                     |
|--------------------|----------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| Gamble et al., 2007 [45] | Bangladesh, adults  | CG (n = 62)—placebo (orally, for 12 weeks) G1 (N = 68)—folic acid 400 µg/day (orally, for 12 weeks) | G1 vs. CG  
- blood: MMA↓, tAs↓, DMA↔  
- urine: DMA↑ (after 1 week) DMA++ (after 12 week) |
| Bozack et al., 2019 [46] | Bangladesh, adults  | CG (n = 90)—placebo (orally, for 12 weeks) G1 (n = 133)—folic acid 400 µg/day (orally, for 12 weeks) G2 (n = 129)—folic acid 800 µg/day (orally, for 12 weeks) | G1, G2 vs. CG  
- plasma: folate↑, homocysteine↓  
- RBC folate↑  
- urine: %iAs↓, %MMAs↓, %DMAs↑ |
| Peters et al., 2015 [47] | Bangladesh, adults  | CG (n = 102)—placebo (orally, for 12 weeks) G1 (n = 153)—folic acid 400 µg/day (orally, for 12 weeks) G2 (n = 151)—folic acid 800 µg/day (orally, for 12 weeks) | G1 vs. CG  
- plasma folate↑, RBC folate↑, geometric mean of blood tAs↑, percentage decline in geometric mean blood tAs from baseline↓ |
|                    |                      | G1 (n = 68)—folic acid 400 µg/day (orally, for 12 weeks) and after that placebo (orally, for 12 weeks) G2 (n = 60)—folic acid 800 µg/day (orally, for 12 weeks) and after that placebo (orally, for 12 weeks) G1a (n = 65)—folic acid 400 µg/day (orally, for 24 weeks) G2a (n = 69)—folic acid 800 µg/day (orally, for 24 weeks) | G2 vs. G1  
- urine: %MMAs↓ |
|                    |                      | G1 (n = 76)—folic acid 400 µg/day (orally, for 24 weeks) and after that placebo (orally, for 24 weeks) G2 (n = 74)—folic acid 800 µg/day (orally, for 24 weeks) and after that placebo (orally, for 24 weeks) G1a (n = 77)—folic acid 400 µg/day (orally, for 24 weeks) G2a (n = 77)—folic acid 800 µg/day (orally, for 24 weeks) | G1a, G2a vs. G1, G2  
- urine: %iAs↓, %MMAs↓, %DMAs↑ |
|                    |                      |                                                                                   | G2, G2a vs. CG  
- geometric mean of blood tAs↓  
- G1a vs. G1  
- geometric mean of blood tAs↑, percentage decline in geometric mean of urinary and blood tAs↑  
- G2a vs. G2  
- geometric mean of blood tAs↑, percentage decline in geometric mean of urinary and blood tAs↑ |
| Reference            | Research Model                           | Study Description                                                                                                                                                                                                 | Main Results                                                                                                                                                                                                 |
|----------------------|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Bozack et al., 2020  | Bangladesh, adults                       | CG (n = 104)—placebo (orally, for 12 weeks)  
G1 (n = 156)—folic acid 400 µg/day (orally, for 12 weeks)  
G2 (n = 154)—folic acid 800 µg/day (orally, for 12 weeks) | G1 vs. CG participants with betaine concentrations below the median: urine: decreases in ln(%iAs)↑, decrease in %MMAs↑, increases in %DMAs↑  
G2 vs. CG participants with betaine concentrations below the median: urine: decreases in ln(%iAs)↑, decreases in %DMAs↑ |
| Kordas et al., 2017  | Mexico, children (6–7 years)              | CG (n = 151)—placebo (orally, for 6 months)  
G1 (n = 144)—zinc oxide 30 mg/day (orally, for 6 months) | G1 vs. CG urine: %DMA↓, %MMA↔, %iAs↔, tAs↔  
G1, G2 vs. CG plasma: choline↑, betaine↑, percentage decrease in DMG↑ |
| Hall et al., 2016    | Bangladesh, adults                       | CG (n = 101)—placebo (participants received arsenic-removal water filters and had been drinking water from wells with water As concentration >50 µg/L at least 3 years)  
G1 (n = 152)—folic acid 400 µg/day (orally, for 12 weeks) and after that placebo (participants received arsenic-removal water filters and had been drinking water from wells with water As concentration >50 µg/L at least 3 years)  
G2 (n = 149)—folic acid 800 µg/day (orally, for 12 weeks) and after that placebo (participants received arsenic-removal water filters and had been drinking water from wells with water As concentration >50 µg/L at least 3 years) | G1, G2 vs. CG G1 vs. G2 plasma: choline↑, betaine↑, percentage decrease in DMG↑ |
| Dani, 2019           | Women (16 year-old)—chronic arsenic intoxication | ex juvantibus therapy: torasemide 10–20 mg/day, thiamine 300 mg/day, magnesium 5 mg/day, folic acid 5 mg/day and metamizole and simeticon (on-demand) | nuchal scalp hair shafts: As—undetectable  
morning urine: As—undetectable  
afternoon urine: As 50 nmol/L  
symptoms (leg cramps, abdominal pains)↓ |
| Howe et al., 2017    | Bangladesh, adults                       | CG (n = 104)—placebo (orally, for 12 weeks)  
G1 (n = 156)—folic acid 400 µg/day (orally, for 12 weeks) | G1 vs. CG blood: PTHMs++  
G2 vs. CG |
| Ghose et al., 2014   | India, patients with symptoms of arsenic toxicity | CG (n = 45)—drinking arsenic free water (orally, for 6 months)  
G1 (n = 32)—folic acid 5 mg/day (orally, for 6 months) | G1 vs. CG skin score↓, systemic disease score↑ (overall: clinical symptoms of arsenicosis↓) |

↑—significant increase; ↓—significant decrease; ↔—no significant changes; CG—control group; DMA—dimethylarsinic acid; DMAs—dimethyl arsenical species; DMG—dimethylglycine; G1—group 1; G2—group 2; iAs—inorganic arsenic; MMA—monomethylarsonic acid; MMAs—monomethyl arsenical species; PTHMs—post-translational histone modifications; RBC—red blood cell; tAs—total arsenic species.
3.4. Blood and Tissues Nutrients Concentration

Table 4 presents a summary of the results of 29 human studies in which the relationship between the concentrations of dietary compounds (in blood and other tissue) and As metabolism was analyzed, as well as severity of adverse health effects associated with As exposure.

3.4.1. Blood Nutrient Concentration—iAs Metabolism

Eight studies analyzed the relationship between blood micronutrient concentrations and urinary As metabolites in children. No relationship was observed between plasma vitamin B\textsubscript{6} levels and urinary excretion of As metabolites (%MMA, %DMA, and %iAs) [24]. The results of three studies [24,25,54] did not demonstrate the relationship between vitamin B\textsubscript{12} concentration in the plasma/serum and As metabolites in the urine. In turn, the results of two studies demonstrated an increase in the %DMA and a decrease in the %MMA, %iAs in the urine of the group of children with high concentrations of vitamin B\textsubscript{12} and folate in their plasma [55] in the second study showed a positive association between serum vitamin B\textsubscript{12} concentration and urinary concentrations of DMA [56]. Additionally, results of three studies showed no relationship between the concentration of plasma/serum folate and urinary %MMA [24,54,57]. Plasma/serum folate concentration was positively associated with the percentage and concentration of DMA in the urine [56–58] and negatively with urinary %iAs [54,57]. In contrast, in the study by Kurzius-Spencer et al. [24], folate concentration in the serum had no relationship with urinary %DMA and %iAs, and in the study by Desai et al. [25], no relationship was observed with any urinary iAs metabolites.

Family iAs metabolism was only analyzed in one study. A strong pattern of metabolism was shown between siblings. Additionally, in siblings, positive correlations between urinary iAs/methylated As, monomethylarsonate/dimethylarsinate a methionine, vitamin B\textsubscript{6}, B\textsubscript{12} folate in the blood were observed. These correlations between parents and children were much lower [59].

The relationship between nutritional status and iAs metabolism has also been analyzed in the adult population (12 studies).

One study found that plasma vitamin B\textsubscript{6} concentration was not associated with the urinary excretion of As metabolites (%MMA, %DMA, and %iAs) [24].

A lower %MMA and higher %DMA in the urine were observed in adults with a low concentration of vitamin B\textsubscript{12} in the plasma compared to individuals with a higher concentration of this vitamin. The study also noted that the concentration of vitamin B\textsubscript{12} in the plasma was positively associated with urinary %MMA, but inversely associated with urinary %iAs. Such a relationship was stronger in the group of subjects with an adequate folate concentration in the plasma [60]. The study by Zhu et al. [56] demonstrated that serum vitamin B\textsubscript{12} concentration was positively associated with urinary concentrations of DMA. However, the results of other studies showed no relationship between plasma and serum vitamin B\textsubscript{12} concentration and urinary As metabolites [24,61].

In contrast, three studies found no relationship between plasma/serum vitamin B\textsubscript{12} concentrations and urinary excretion of As metabolites (%MMA, %DMA, and %iAs) in pregnant women [62–64]. Only the study by Laine et al. [62] demonstrated a negative correlation between maternal serum vitamin B\textsubscript{12} with tAs in the urine. Moreover, in women, the concentration of vitamin B\textsubscript{12} in the plasma was inversely associated with arsenate [65] and positively associated with %iAs [62] in cord blood.

In one study, serum/plasma folate concentration was positively associated with urinary %MMA [58], while in the study by Gamble et al. [61], it was negatively associated with urinary %MMA. Two studies demonstrated a positive association between folate concentration in the serum/plasma and urinary %DMA [56,61]. In turn, the results of another study did not report such a relationship [58]. Moreover, in the study by Gamble et al. [61] plasma folate concentration was negatively associated with urinary %iAs. In turn, in the study by Kurzius-Spencer et al. [24] no relationship was shown between serum folate levels and urinary iAs metabolites.
In a Bangladeshi population, individuals with low plasma folate concentrations showed a correlation between decreased ratio of glutathione-to-glutathione disulfide and higher blood levels of tAs, as well as having increased %MMA and decreased %DMA in the urine [66].

The study by Chung et al. [67] analyzed the relationship between gene polymorphisms, iAs metabolism and plasma folate. Abnormal iAs metabolism and decreased plasma folate levels were observed in patients with urothelial carcinoma. Subjects with the 5,10-methylenetetrahydrofolate reductase CT or TT genotype had lower percentage dimethylarsenic acid in the urine and a lower folate concentration in the plasma than those with the CC genotype. A positive correlation was also observed between plasma folate concentration and percentage urinary dimethylarsenic acid in the control group.

In Bangladeshi women, folate concentration in the plasma/serum was inversely associated with arsenate in the maternal blood [65], and in pregnant women negatively correlated with percentage monomethyl arsenicals in the cord serum [62]. In contrast, three studies did not demonstrate significant correlations between plasma folate levels and urinary As metabolites in pregnant women [62–64]. Only in women with both higher As exposure level and plasma folate concentration was a reduced iAs level in the urine noted [63].

Two studies reported no significant relationship between plasma zinc concentrations and urinary As metabolites in pregnant women [62,64]. Only in subjects with the highest exposure level were higher plasma zinc concentrations associated with increased %MMA and %iAs, and decreased %DMA [63].

3.4.2. Blood and Tissue Nutrient Concentration—Toxicity of As

Many studies have focused on analyzing the relationship between nutritional status and As concentrations in various tissues and adverse health effects in individuals exposed to As.

The relationship between As exposure, nutritional status, and DNA methylation was analyzed in three studies. In elderly men, no association was observed between the plasma concentrations of vitamin B$_6$ and B$_{12}$ and DNA methylation. However, in men with a low concentration of folate in the plasma, a positive association with one repetitive element (increased Alu DNA methylation) was observed, whereas in men with a higher concentration of plasma folate, the effect was the opposite [68]. Similarly, the study in Bangladeshi adults with high plasma folate concentration (above 9 nmol/L) showed negative correlation between urinary or plasma tAs and methylation of peripheral blood leukocyte DNA (lower [3H]-methyl incorporation) [69]. In turn, in women with folate deficiency in the plasma, an inversely association was observed between the tAs concentration in toenail and total histone 3 levels in the plasma [70].

 Howe et al. [52] demonstrated positive associations between the plasma concentration of vitamin B$_{12}$ (among women) and choline (among men) and global levels of post-translational histone modifications.

Several studies have reported the relationship between blood concentrations of nutrients and the risk of disease development or the severity of adverse body changes associated with an exposure to As.

A higher odds ratio of type 1 diabetes by the percentage of monomethylates As was observed in individuals with a higher concentration of plasma folate (stronger relationship between percentage monomethylated As and type 1 diabetes). No significant relationship was shown for type 2 diabetes between percentage monomethylates As and plasma folate or vitamin B$_{12}$ concentration [71]. It was observed in the study by Chung et al. [72] that low a concentration of folate in the plasma, global 5-methyl-2′-deoxycytidine levels, and a high concentration of total urinary As levels was related to an increased risk of urothelial carcinoma. The study conducted in a West Bengal population, did not demonstrate any relationship between the concentration of folate, methionine, vitamin B$_6$, vitamin B$_{12}$ in the blood and the susceptibility to develop skin lesions [73]. Subjects with low plasma
folate concentrations had an increased risk of skin lesions, whereas no such relationship was observed in subjects with lower vitamin B$_{12}$ concentrations [74].

Low concentrations of folate and vitamin B$_{12}$ in the plasma were indirectly (through association with decreased iAs metabolism) related to an increased childhood developmental delay (increase in odds ratio of developmental delay) [55]. In the study by Desai et al. [43], higher broad math scores were observed in subjects with higher vitamin B$_{12}$ in the serum and tAs concentration in the urine.

In subjects exposed to As, zinc and tAs concentrations in different tissues were analyzed. In pregnant women living in Wuhan (the largest industrial city), a positive correlation between tAs and zinc concentration in blood was observed [75]. On the other hand, in patients with blackfoot disease, decreased zinc concentration in the hair, urine, blood as well as increased tAs concentration in hair and urine were observed [76–78]. On the other hand, in groups of workers, a higher concentration of tAs in the lung tissue and in the blood was observed, but no decreased concentration of zinc in these tissues was shown [79,80]. Moreover, in the study by Tutkun et al. [80], the correlation between Zn and tAs was negative and in the workers group higher levels of inflammatory markers (interleukins 6, 10 and tumor necrosis factor-α) was also observed, but no correlation was observed between these cytokines and Zn.

3.4.3. Concentration of Nutrients in Blood and Other Tissues—Summary

The results of human studies on the relationship between the blood concentrations of dietary compounds and iAs metabolism are also inconclusive. They indicate that the concentration of dietary compounds in the blood may be related to iAs metabolism and contribute to its elimination from the body. This is indicated by several studies in which it was observed that the blood concentration of vitamin B$_{12}$ and folate correlated with iAs metabolism. However, some of the correlations between the blood concentration of these nutrients (folate, B$_6$, B$_{12}$, and zinc) and the urinary content of various forms of iAs suggest that these nutrients may or may not impair iAs methylation.

Three studies showed that nutritional status (choline, vitamin B$_{12}$, folate—higher plasma/serum concentrations) may be related to a decrease in adverse health effects (affected methylation DNA, histone modification, and children achievement) in individuals exposed to As. The results of this study are in line with expectations, since the appropriate status of these nutrients can alleviate the adverse health effects associated with exposure to As. Numerous studies also observed a relationship between concentration of these nutrients (folate—low and higher plasma concentration; vitamin B$_{12}$—low plasma concentration) and increased risk of disease and adverse body changes associated with an exposure to As (increased DNA methylation, risk of type 1 diabetes and urothelial carcinoma, skin lesions, and developmental delay). Folate deficiency (five studies) and vitamin B12 deficiency (one study) enhanced adverse effects of iAs exposure, and only in one study higher concentration of folate exacerbated them. These results indicate that both a deficiency and an excess of these compounds may contribute to enhancing the toxicity of As. The level of exposure to iAs does not appear to be a differentiating factor, as the adverse effects associated with folic acid deficiency occurred in populations with low (including elderly men, preschool children, and women) and high exposure (cases with skin lesions and urothelial carcinoma). In several studies, no relationships (or the relationship was unclear) between blood/plasma concentration of methionine, vitamins B$_6$, B$_{12}$, folate a DNA methylation, risk of type 2 diabetes and skin lesions were found. Moreover, in pregnant women, patients with blackfoot disease and workers exposed to As, elevated tAs concentrations in many tissues were connected with disturbances in zinc concentrations.
Table 4. Relationship between concentration of dietary compound in blood and other tissues and iAs metabolism and health effects related to As exposure.

| Reference                     | Population                          | Measure of Component Status | Main Results                                                                 |
|-------------------------------|-------------------------------------|-----------------------------|------------------------------------------------------------------------------|
| Hall et al., 2009 [54]       | Bangladesh, children (6 years old)  | plasma: vitamin $B_{12}$    | urine: %DMA (NS), %MMA (NS), %iAs (NS)                                       |
|                               |                                     | plasma: folate              |                                                                              |
| Skroder Loveborn et al., 2016 [57] | Bangladesh, children (9 years old) | plasma: folate              | urine: %DMA (+), %MMA (NS), %iAs (−)                                         |
| Lin et al., 2019 [55]        | Taiwan, children (preschool aged)   | plasma: vitamin $B_{12}$ and folate | ORs of development delay↑ (in the group with low concentrations vitamin $B_{12}$ and folate) |
| Desai et al., 2020 [25]      | Montevideo (Uruguay), children ~7 years | serum: vitamin $B_{12}$, folate | urine: %DMA (NS), %MMA (NS), %iAs (NS)                                       |
| Zhang et al., 2019 [58]      | US, adults and children (≤18 years) | serum: folate               | urine: %DMA (+), MMA (NS) (in the group of children)                        |
| Zhu et al., 2018 [56]        | U.S., adults and children (6–19 years) | serum: vitamin $B_{12}$, folate | urine: %DMA (NS), %MMA (NS), %iAs (NS)                                       |
| Kurzius-Spencer et al., 2017 [24] | U.S., adults and children >6 years  | plasma: vitamin $B_{6}$    | urine: %DMA (NS), %MMA (NS), %iAs (NS), DMA/MMA (NS) (in the groups of adults and children) |
| Chung et al., 2002 [59]      | Chile, adults and children (6–14 years) | blood: methionine, vitamin $B_{6}$, vitamin $B_{12}$, folate | urine: %DMA (NS), %MMA (NS), %iAs (NS), MMA/ASA (−) |
| Hall et al., 2009 [60]       | Bangladesh, adults                  | plasma: vitamin $B_{12}$    | urine: %DMA↑, %MMA↑, %iAs−, %As− (in the vitamin $B_{12}$ deficient group compared to vitamin $B_{12}$ sufficient group) |
| Gamble et al., 2005 [61]     | Bangladesh, adults                  | plasma: vitamin $B_{12}$    | urine: %DMA (NS), %MMA (NS), %iAs (NS)                                       |
| Niedzwiecki et al., 2014 [66] | Bangladesh, adults                  | plasma: folate              | urine: %DMA (+), %MMA (−), %iAs (−)                                         |
| Chung et al., 2010 [67]      | cases with urothelial carcinoma and control group | plasma: folate              | plasma: GSH/GSSG ratio association with urine: %DMA (−), %MMA (+), SMI (+), blood: tAs (−) (in the folate deficient group) |
| Hall et al., 2007 [65]       | Bangladesh, women and children (newborn) | plasma: vitamin $B_{12}$    | cord blood: percentage arsenate (−) (in the group of women)                  |
|                             |                                     | plasma: folate              | blood: percentage arsenate (−) (in the group of women)                       |
| Reference                          | Population                              | Measure of Component Status                      | Main Results                                                                 |
|-----------------------------------|-----------------------------------------|-------------------------------------------------|-------------------------------------------------------------------------------|
| Laine et al., 2018 [62]           | $n = 197$ Mexico, women (pregnant)      | serum: vitamin $\text{B}_12$                    | urine: %DMA (NS), %MMA (NS), %iAs (NS), tAs (−)                                |
|                                   |                                         | serum: folate                                   | cord serum: %iAs (+)                                                           |
|                                   |                                         | urine: %DMA (NS), %MMA (NS), %iAs (NS), tAs (NS) | cord serum: %MMAs (−)                                                         |
| Li et al., 2008 [63]              | $n = 753$ Bangladesh, women (pregnant) | plasma: vitamin $\text{B}_12$, folate, Zn—high and low values | urine: %DMA↔, %MMA↔, %iAs↔ (in the group at the low As exposure level)         |
|                                   |                                         | plasma: folate—high values                      | urine: %iAs↓ (in the group at the highest As exposure level)                  |
|                                   |                                         | plasma: Zn—high values                          | plasma: Zn↓, %MMA↑, %iAs↑, SMI↓ (in the group at the highest As exposure level) |
| Gardner et al., 2011 [64]         | $n = 324$ Bangladesh, women (pregnant) | plasma: vitamin $\text{B}_12$, folate, Zn       | urine: %DMA (NS), %MMA (NS), %iAs (NS)                                        |
| Lambrou et al., 2012 [68]         | $n = 581$ Boston, men (elderly)         | plasma: vitamin $\text{B}_6$, vitamin $\text{B}_12$ | blood: Alu (NS), Long Interspersed Nucleotide Element-1 (NS)                  |
|                                   |                                         | plasma: folate                                   | blood: Alu (+), Long Interspersed Nucleotide Element-1 (NS)                  |
|                                   |                                         |                                                   | (in the low folate group)                                                     |
|                                   |                                         |                                                   | blood: Alu (−), Long Interspersed Nucleotide Element-1 (NS)                  |
|                                   |                                         |                                                   | (in the high folate group)                                                    |
| Pilsner et al., 2007 [69]         | $n = 294$ Bangladesh, adults            | plasma: folate                                   | [%H]-methyl incorporation association with tAs in the urine, plasma (−)        |
|                                   |                                         |                                                   | (in the high folate group)                                                    |
| Tauheed et al., 2017 [70]         | $n = 85$ Bangladesh, women              | plasma: folate                                   | tAs concentration in toenail association with plasma total H3 (−)             |
|                                   |                                         |                                                   | (in the folate deficient group)                                               |
| Howe et al., 2017 [52]            | $n = 324$ Bangladesh, adults            | plasma: choline                                  | peripheral blood mononuclear cells: H3K36me2 (+) (in the men group)           |
|                                   |                                         | plasma: vitamin $\text{B}_12$                    | peripheral blood mononuclear cells: H3K79me2 (+) (in the women group)         |
|                                   |                                         | plasma: folate                                   | peripheral blood mononuclear cells: H3K36me2 (NS), H3K36me3 (NS), H3K79me2 (NS) |
|                                   |                                         |                                                   | (in the men and women group)                                                  |
| Grau-Perez et al., 2017 [71]      | $n = 688$ U.S., adults and children     | plasma: vitamin $\text{B}_12$                    | ORs of type 1 and type 2 diabetes by %monomethylated As↔                       |
|                                   |                                         | plasma: folate—high values                      | ORs of type 1 diabetes by %monomethylated As†                                 |
|                                   |                                         |                                                   | ORs of type 2 diabetes by %monomethylated As↔                                 |
| Chung et al., 2019 [72]           | $n = 534$ Taiwan, cases with urothelial carcinoma and control group | plasma: folate                                   | ORs of urothelial carcinoma† (low folate level and global 5-MedC, high tAs in the urine) |
Table 4. Cont.

| Reference                  | Population                                                                 | Measure of Component Status                             | Main Results                                      |
|----------------------------|---------------------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------|
| Chung et al., 2006 [73]    | West Bengal, cases with skin lesions and control group                    | blood: methionine, vitamin $\text{B}_6$, vitamin $\text{B}_{12}$, folate | ORs of skin lesions $\leftrightarrow$             |
| Pilsner et al., 2009 [74]  | Bangladesh, cases with skin lesions and control group                     | plasma: vitamin $\text{B}_{12}$—low values            | ORs for development skin lesions $\leftrightarrow$ |
|                            |                                                                           | plasma: folate—low values                              | ORs for development skin lesions $\uparrow$       |
| Desai et al., 2020 [43]    | Montevideo (Uruguay), children ~5–8 years                                  | serum: vitamin $\text{B}_{12}$                         | urine: tAs and broad math score (+)               |
| Gong et al., 2020 [75]     | Wuhan, women (pregnant) and control group (non-pregnant)                 | blood: Zn                                             | blood: tAs (+) (in the group of pregnant women)   |
| Wang et al., 1994 [76]     | Taiwan, cases with blackfoot disease and control group                    | hair: Zn                                              | hair: Zn, tAs $\uparrow$ (in the group of patients with blackfoot disease) |
| Tsai et al., 2004 [77]     | Taiwan, cases with blackfoot disease and control group                    | urine: Zn                                             | urine: Zn, tAs $\uparrow$ (in the group of patients with blackfoot disease) |
| Lin and Yang, 1988 [78]    | cases with blackfoot disease and control group                            | blood, serum, urine: Zn                               | blood, serum, urine: Zn $\leftrightarrow$ (in the group of patients with blackfoot disease) |
| Gerhardsson and Nordberg, 1993 [79] | smelter workers and control group (from urban and rural area) | lung tissue: Zn                                       | lung tissue: Zn $\leftrightarrow$, tAs $\uparrow$ |
| Tutkun et al., 2019 [80]   | Ankara, men—workers (exposed to As) and control group                    | serum: Zn                                             | blood: tAs $\uparrow$, Zn $\leftrightarrow$, IL-6 $\leftrightarrow$, IL-10 $\uparrow$, TNF-α $\uparrow$ (in the workers group) correlation tAs—Zn $\leftrightarrow$ (in the workers group) |

$\uparrow$—significant increase; $\downarrow$—significant decrease; $\leftrightarrow$—no significant changes; (+)—positively association; (−)—negatively association; (NS)—no significant association; As—arsenic; DMA—dimethylarsinic acid; GSH/GSSG—glutathione/glutathione disulfide; H3—histone 3; H3K36me2—histone 3 lysine 36 dimethylation; H3K36me3—histone 3 lysine 36 trimethylation; H3K79me2—histone 3 lysine 79 dimethylation; iAs—inorganic arsenic; IL-6—Interleukin 6; IL-10—interleukin 10; MMA—monomethylarsonic acid; MMA/DMA—monomethylarsonate/dimethylarsinate; MMAs—monomethyl arsenical species; ORs—odds ratios; SMI—secondary methylation index; tAs—total arsenic species; TNF-α—tumor necrosis factor-α; Zn—zinc; 5-MedC—5-methyl-2′deoxycytidine.
4. Conclusions

Many studies have also focused on analyzing the relationship between dietary compounds (intake, supplementation mainly folic acid, and blood concentrations), and iAs metabolism, as well as exposure-related disorders. The intake and blood concentrations of certain dietary compounds (methionine, choline, vitamin B\textsubscript{2}, B\textsubscript{6}, B\textsubscript{12}, folic acid, and zinc) showed a relationship with an improvement in iAs metabolism and were associated with reduction in adverse health effects. It was also shown that not only the deficiency (folate), but also the excess of some dietary compounds (vitamin B\textsubscript{12}, folic acid, zinc) may impair iAs metabolism and may increase adverse health effects. Human studies, to date, are inconclusive, because many factors influenced the results. This signals the need for a more detailed analysis of the relationship between the nutrient intake of involved in iAs metabolism, nutritional status as well as the severity and source of iAs exposure. Considering the promising results of the studies conducted so far, it seems reasonable that individuals exposed to iAs should consume natural products rich in methionine, choline, folic acid, B vitamins (B\textsubscript{2}, B\textsubscript{6}, B\textsubscript{12}) and zinc. Products rich in methionine (meat: turkey, beef, pork and milk, tofu, and Brazil nuts), choline (eggs, beans, and broccoli; meat: chicken, pork, and beef), folic acid (green leafy vegetables), B-group vitamins (meat, eggs, dairy product, leafy greens, and legumes), and zinc (meat, nuts, and cereal products). Nutrition education focusing on an adequate dietary intake of methionine, choline, zinc, folic acid, and B vitamins (B\textsubscript{2}, B\textsubscript{6}, and B\textsubscript{12})—nutrients which potentially have modulating effects in iAs metabolism and toxicity—should be used in prevention efforts for populations exposed to iAs.

Author Contributions: Conceptualization, M.S. and L.K.; methodology, M.S. and L.K.; investigation, M.S. and L.K.; data curation, M.S. and L.K.; writing—original draft preparation, M.S.; writing—review and editing, L.K. Both authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Medunčić, G.; Fiket, Ž.; Ivanić, M. Arsenic contamination status in Europe, Australia, and other parts of the world. In Arsenic in Drinking Water and Food; Srivastava, S., Ed.; Springer: Singapore, 2020; pp. 183–233.
2. WHO. Exposure to arsenic: A major public health concern. In Preventing Disease through Healthy Environments; Department of Public Health, Environmental and Social Determinants of Health, World Health Organization: Geneva, Switzerland, 2019.
3. Agency for Toxic Substances and Disease Registry. Addendum to Toxicological Profile for Arsenic; Agency for Toxic Substances and Disease Registry, Division of Toxicology and Human Health Sciences: Atlanta, GA, USA, 2016; pp. 1–189.
4. European Food Safety Authority (EFSA). Scientific report on the chronic dietary exposure to inorganic arsenic. EFSA J. 2021, 19, 6380.
5. Drobna, Z.; Styblo, M.; Thomas, D.J. An overview of arsenic metabolism and toxicity. Curr. Protoc. Toxicol. 2009, 42, 4.31.1–4.31.6. [PubMed]
6. Vahter, M. Mechanisms of arsenic biotransformation. Toxicology 2002, 181–182, 211–217. [CrossRef]
7. Styblo, M.; Del Razo, L.M.; Vega, L.; Germolec, D.R.; LeCluyse, E.L.; Hamilton, G.A.; Reed, W.; Wang, C.; Cullen, W.R.; Thomas, D.J. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch. Toxicol. 2000, 74, 289–299. [CrossRef]
8. IARC. Summaries and evaluations: Arsenic in drinking-water (Group 1). In IARC Monographs on the Evaluation of Carcinogenic Risk to Humans, Volume 84; IARC: Lyon, France, 2004; pp. 41–267. ISBN 92-832-1284-3.
9. Smith, A.H.; Biggs, M.L.; Moore, L.; Haque, R.; Steinmaus, C.; Chung, J.; Hernandez, A.; Lopipero, P. Cancer Risks from Arsenic in Drinking Water. In Arsenic Exposure and Health Effects III; Chappel, W.R., Abernathy, C.O., Calderon, R.L., Eds.; Elsevier Science: New York, NY, USA, 1999; pp. 191–199.
10. IARC. Arsenic, Metals, Fibres, and Dusts. In IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 100 C; IARC: Lyon, France, 2012; pp. 41–93. ISBN 978-92-832-1320-8.
11. Wang, W.; Xie, Z.; Lin, Y.; Zhang, D. Association of inorganic arsenic exposure with Type 2 Diabetes Mellitus: A meta-analysis. J. Epidemiol. Community Health 2014, 68, 176–184. [CrossRef]

12. Pan, W.C.; Seow, W.J.; Kile, M.L.; Hoffman, E.B.; Quamruzzaman, Q.; Rahman, M.; Mahiuddin, G.; Mostofa, G.; Lu, Q.; Christiani, D.C. Association of low to moderate levels of arsenic exposure with risk of type 2 diabetes in Bangladesh. Am. J. Epidemiol. 2013, 178, 1563–1570. [CrossRef] [PubMed]

13. Tseng, C.H.; Huang, Y.K.; Huang, Y.L.; Chung, C.J.; Yang, M.H.; Chen, C.J.; Hsueh, Y.M. Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in Blackfoot disease-hyperendemic villages in Taiwan. Toxicol. Appl. Pharmacol. 2005, 206, 299–308. [CrossRef] [PubMed]

14. Argos, M.; Kalra, T.; Pierce, B.L.; Chen, Y.; Parvez, F.; Islam, T.; Ahmed, A.; Hasan, R.; Hasan, K.; Sarwar, G.; et al. A prospective study of arsenic exposure from drinking water and incidence of skin lesions in Bangladesh. Am. J. Epidemiol. 2011, 174, 185–194. [CrossRef]

15. Parvez, F.; Chen, Y.; Yunus, M.; Olopade, C.; Segers, S.; Slavkovich, V.; Argos, M.; Hasan, R.; Ahmed, A.; Islam, T.; et al. Arsenic exposure and impaired lung function. Findings from a large population-based prospective cohort study. Am. J. Respir. Crit. Care Med. 2013, 188, 813–819. [CrossRef]

16. Tyler, C.R.; Allan, A.M. The effects of arsenic exposure on neurological and cognitive dysfunction in human and rodent studies: A review. Curr. Environ. Health Rep. 2014, 1, 132–147. [CrossRef]

17. Rodrigues, E.G.; Bellinger, D.C.; Valeri, L.; Hasan, M.O.; Quamruzzaman, Q.; Golam, M.; Kile, M.L.; Christiani, D.C.; Wright, R.O.; Mazumdar, M. Neurodevelopmental outcomes among 2- to 3-year-old children in Bangladesh with elevated blood lead and exposure to arsenic and manganese in drinking water. Environ. Health 2016, 15, 44. [CrossRef]

18. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009, 6, e1000097. [CrossRef]

19. Xu, Y.; Wang, H.; Wang, Y.; Zheng, Y.; Sun, G. Effects of folate on arsenic toxicity in Chang human hepatocytes: Involvement of folate antioxidant properties. Toxicol. Lett. 2010, 195, 44–50. [CrossRef] [PubMed]

20. Ma, Y.; Zhang, C.; Gao, X.B.; Luo, H.Y.; Chen, Y.; Li, H.; Ma, X.; Lu, C.L. Folic acid protects against arsenic-mediated embryo toxicity by up-regulating the expression of Dvr1. Sci. Rep. 2015, 5, 16093. [CrossRef] [PubMed]

21. Wong, C.P.; Dashner-Titus, E.J.; Alvarez, S.C.; Chase, T.T.; Hudson, L.G.; Ho, E. Zinc deficiency and arsenic exposure can act both independently or cooperatively to affect zinc status, oxidative stress, and inflammatory response. Biol Trace Elem. Res. 2019, 191, 370–381. [CrossRef] [PubMed]

22. Sun, X.; Zhou, X.; Du, L.; Liu, W.; Liu, Y.; Hudson, L.G.; Liu, K.J. Arsenite binding-induced zinc loss from PARP-1 is equivalent to zinc deficiency in reducing PARP-1 activity, leading to inhibition of DNA repair. Toxicol. Appl. Pharmacol. 2014, 274, 313–318. [CrossRef]

23. Desai, G.; Vahter, M.; Queirolo, E.I.; Peregalli, F.; Mañay, N.; Millen, A.E.; Yu, J.; Browne, R.W.; Kordas, K. Vitamin B-6 intake is modestly associated with arsenic methylation in Uruguayan children with low-level arsenic exposure. J. Nutr. 2020, 150, 1223–1229. [CrossRef]

24. Kuruzis-Spencer, M.; da Silva, V.; Thomson, C.A.; Hartz, V.; Hsu, C.H.; Burgess, J.L.; O’Rourke, M.K.; Harris, R.B. Nutrients in one-carbon metabolism and urinary arsenic methylation in the National Health and Nutrition Examination Survey (NHANES) 2003–2004. Sci. Total Environ. 2017, 607–608, 381–390. [CrossRef]

25. Desai, G.; Millen, A.E.; Vahter, M.; Queirolo, E.I.; Peregalli, F.; Mañay, N.; Yu, J.; Browne, R.W.; Kordas, K. Associations of dietary intakes and serum levels of folate and vitamin B-12 with methylation of inorganic arsenic in Uruguayan children: Comparison of findings and implications for future research. Environ. Res. 2020, 189, 109935. [CrossRef]

26. Kordas, K.; Queirolo, E.I.; Mañay, N.; Peregalli, F.; Hsiao, P.Y.; Lu, Y.; Vahter, M. Low-level arsenic exposure: Nutritional and dietary predictors in first-grade Uruguayan children. Environ. Res. 2016, 147, 16–23. [CrossRef]

27. Beck, J.E.; Gamble, M.V.; Chen, Y.; Graziano, J.H.; Slavkovich, V.; Parvez, F.; Baron, J.A.; Howe, G.R.; Ahsan, H. Consumption of folate-related nutrients and the metabolism of arsenic in Bangladesh. Am. J. Clin. Nutr. 2007, 85, 1367–1374. [CrossRef]

28. López-Carrillo, L.; Gamboa-Loira, B.; Becerra, W.; Hernández-Alcaraz, C.; Hernández-Ramírez, R.U.; Gandolfi, A.J.; Franco-Marina, F.; Cebrián, M.E. Dietary micronutrient intake and its relationship with arsenic metabolism in Mexican women. Environ. Res. 2016, 151, 445–450. [CrossRef]

29. Beck, J.E.; Nieves, J.W.; Chen, Y.; Parvez, F.; Brandt-Rauf, P.W.; Graziano, J.H.; Slavkovich, V.; Howe, G.R.; Ahsan, H. Dietary intake of methionine, cysteine, and protein and urinary arsenic excretion in Bangladesh. Environ. Health Perspect. 2009, 117, 99–104. [CrossRef] [PubMed]

30. Spratlen, M.J.; Gamble, M.V.; Grau-Perez, M.; Kuo, C.C.; Best, L.G.; Yracheta, J.; Francesconi, K.; Goessler, W.; Mossavar-Rahmani, Y.; Hall, M.; et al. Arsenic metabolism and one-carbon metabolism at low-moderate arsenic exposure: Evidence from the Strong Heart Study. Food Chem. Toxicol. 2017, 105, 387–397. [CrossRef] [PubMed]

31. Spratlen, M.J.; Grau-Perez, M.; Umanes, J.G.; Yracheta, J.; Best, L.G.; Francesconi, K.; Goessler, W.; Balakrishnan, P.; Cole, S.A.; Gamble, M.V.; et al. Arsenic, one carbon metabolism and diabetes-related outcomes in the Strong Heart Family Study. Environ. Int. 2018, 121, 728–740. [CrossRef] [PubMed]

32. Bommarito, P.A.; Xu, X.; González-Horta, C.; Sánchez-Ramírez, B.; Ballinas-Casarribias, L.; Luna, R.S.; Pérez, S.R.; Ávila, J.E.H.; García-Vargas, G.G.; Del Razo, L.M.; et al. One-carbon metabolism nutrient intake and the association between body mass index and urinary arsenic metabolites in adults in the Chihuahua cohort. Environ. Int. 2019, 123, 292–300. [CrossRef] [PubMed]
33. Steinmaus, C.; Carrigan, K.; Kalman, D.; Atallah, R.; Yuan, Y.; Smith, A.H. Dietary intake and arsenic methylation in a U.S. population. Environ. Health Perspect. 2005, 113, 1133–1139. [CrossRef]

34. Argos, M.; Rathouz, P.J.; Pierce, B.L.; Kalra, T.; Parvez, F.; Slavkovich, V.; Ahmed, A.; Chen, Y.; Ahsan, H. Dietary B vitamin intakes and urinary total arsenic concentration in the Health Effects of Arsenic Longitudinal Study (HEALS) cohort, Bangladesh. Eur. J. Nutr. 2010, 49, 473–481. [CrossRef]

35. Howe, C.G.; Li, Z.; Zens, M.S.; Palys, T.; Chen, Y.; Channon, J.Y.; Karagas, M.R.; Farzan, S.F. Dietary B vitamin intake is associated with lower urinary monomethyl arsenic and oxidative stress marker 15-F2t-isoprostane among New Hampshire adults. J. Nutr. 2017, 147, 2289–2296. [CrossRef]

36. Chen, Y.; Factor-Litvak, P.; Howe, G.R.; Graziano, J.H.; Brandt-Rauf, P.; Parvez, F.; van Geen, A.; Ahsan, H. Arsenic exposure from drinking water, dietary intakes of B vitamins and folate, and risk of high blood pressure in Bangladesh: A population-based, cross-sectional study. Am. J. Epidemiol. 2007, 165, 541–552. [CrossRef]

37. Koutrots, S.; Baris, D.; Waddell, R.; Beane Freeman, L.E.; Colt, J.S.; Schwenn, M.; Johnson, A.; Ward, M.H.; Hossain, G.M.; Moore, L.E.; et al. Potential effect modifiers of the arsenic-bladder cancer risk relationship. Int. J. Cancer 2018, 143, 2640–2646. [CrossRef]

38. Melkonian, S.; Argos, M.; Chen, Y.; Parvez, F.; Pierce, B.; Ahmed, A.; Islam, T.; Ahsan, H. Intakes of several nutrients are associated with incidence of arsenic-related keratotic skin lesions in Bangladesh. J. Nutr. 2012, 142, 2128–2134. [CrossRef]

39. Deb, D.; Biswas, A.; Ghose, A.; Das, A.; Majumdar, K.K.; Guha Mazumder, D.N. Nutritional deficiency and arsenical manifestations: A perspective study in an arsenic-endemic region of West Bengal, India. Public Health Nutr. 2012, 16, 1644–1655. [CrossRef] [PubMed]

40. Mitra, S.R.; Mazumder, D.N.G.; Basu, A.; Block, G.; Haque, R.; Samanta, S.; Ghosh, N.; Smith, M.M.H.; von Ehrenstein, O.S.; Smith, A.H. Nutritional factors and susceptibility to arsenic-caused skin lesions in West Bengal, India. Environ. Health Perspect. 2004, 112, 1104–1109. [CrossRef] [PubMed]

41. Zablotska, L.B.; Chen, Y.; Graziano, J.H.; Parvez, F.; van Geen, A.; Howe, G.R.; Ahsan, H. Protective effects of B vitamins and antioxidants on the risk of arsenic-related skin lesions in Bangladesh. Environ. Health Perspect. 2008, 116, 1056–1062. [CrossRef] [PubMed]

42. Desai, G.; Barg, G.; Queirolo, E.I.; Vahter, M.; Peregalli, F.; Mañay, N.; Kordas, K. A cross-sectional study of general cognitive abilities among Uruguayan school children with low-level arsenic exposure, potential effect modification by methylation capacity and dietary folate. Environ. Res. 2018, 164, 124–131. [CrossRef] [PubMed]

43. Desai, G.; Barg, G.; Vahter, M.; Queirolo, E.I.; Peregalli, F.; Mañay, N.; Millen, A.E.; Yu, J.; Browne, R.W.; Kordas, K. Low level arsenic exposure, B-vitamins, and achievement among Uruguayan school children. Int. J. Hyg. Environ. Health 2020, 223, 124–131. [CrossRef]

44. Gruber, J.F.; Karagas, M.R.; Gilbert-Diamond, D.; Bagley, P.J.; Zens, M.S.; Sayarath, V.; Punshon, T.; Morris, J.S.; Cottingham, K.L. Associations between toenail arsenic concentration and dietary factors in a New Hampshire population. Nutr. J. 2012, 11, 45. [CrossRef]

45. Gamble, M.V.; Liu, X.; Slavkovich, V.; Pilsner, J.R.; Ilievski, V.; Factor-Litvak, P.; Levy, D.; Alam, S.; Islam, M.; Parvez, F.; et al. Folic acid supplementation lowers blood arsenic. Am. J. Clin. Nutr. 2008, 88, 1202–1209. [CrossRef]

46. Bozack, A.K.; Hall, M.N.; Liu, X.; Ilievski, V.; Lomax-Luu, A.M.; Parvez, F.; Siddique, A.B.; Shahriar, H.; Uddin, M.N.; Islam, T.; et al. Folic acid supplementation enhances arsenic methylation: Results from a folic acid and creatine supplementation randomized controlled trial in Bangladesh. Am. J. Clin. Nutr. 2019, 109, 380–391. [CrossRef]

47. Peters, B.A.; Hall, M.N.; Liu, X.; Parvez, F.; Sanchez, T.R.; van Geen, A.; Mey, J.L.; Siddique, A.B.; Shahriar, H.; Uddin, M.N.; et al. Folic acid and creatine as therapeutic approaches to lower blood arsenic: A randomized controlled trial. Environ. Health Perspect. 2015, 123, 1294–1301. [CrossRef]

48. Bozack, A.K.; Howe, C.G.; Hall, M.N.; Liu, X.; Slavkovich, V.; Ilievski, V.; Lomax-Luu, A.M.; Parvez, F.; Siddique, A.B.; Shahriar, H.; et al. Betaine and choline status modify the effects of folic acid and creatine supplementation on arsenic methylation in a randomized controlled trial of Bangladeshi adults. J. Nutr. 2020. [CrossRef] [PubMed]

49. Kordas, K.; Roy, A.; López, P.; García-Vargas, G.; Cebrían, M.E.; Vera-Aguilar, E.; Rosado, J.L. Iron and zinc supplementation does not impact urinary arsenic excretion in Mexican school children. J. Pediatr. 2017, 185, 205–210. [CrossRef] [PubMed]

50. Hall, M.N.; Howe, C.G.; Liu, X.; Caudill, M.A.; Malyshova, O.; Ilievski, V.; Lomax-Luu, A.M.; Parvez, F.; Siddique, A.B.; Shahriar, H.; et al. Supplementation with folic acid, but not creatine, increases plasma betaine, decreases plasma dimethylglycine, and prevents a decrease in plasma choline in arsenic-exposed Bangladeshi adults. J. Nutr. 2016, 146, 1062–1067. [CrossRef] [PubMed]

51. Dani, S.U. A curious association of chronic homeopathic arsenic ingestion with nonspecific symptoms in a Swiss teenager. Swiss Med. Wkly. 2019, 149, w20071. [CrossRef]

52. Howe, C.G.; Liu, X.; Hall, M.N.; Ilievski, V.; Caudill, M.A.; Malyshova, O.; Lomax-Luu, A.M.; Parvez, F.; Siddique, A.B.; Shahriar, H.; et al. Sex-specific associations between one-carbon metabolism indices and posttranslational histone modifications in arsenic-exposed Bangladeshi adults. Cancer Epidemiol. Biomarkers Prev. 2017, 26, 261–269. [CrossRef] [PubMed]

53. Ghose, N.; Majumdar, K.K.; Ghose, A.K.; Saha, C.K.; Nandy, A.K.; Mazumder, D.N.G. Role of folic acid on symptoms of chronic arsenic toxicity. Int. J. Prev. Med. 2014, 5, 89–98.
54. Hall, M.N.; Liu, X.; Slavkovich, V.; Ilievski, V.; Pilsnr, J.R.; Alam, S.; Factor-Litvak, P.; Graziano, J.H.; Gamble, M.V. Folate, cobalamin, cysteine, homocysteine, and arsenic metabolism among children in Bangladesh. *Environ. Health Perspect.* 2009, 117, 825–831. [CrossRef]

55. Lin, Y.C.; Chung, C.J.; Huang, Y.L.; Hsieh, R.L.; Huang, P.T.; Wu, M.Y.; Ao, P.L.; Shieue, H.S.; Huang, S.R.; Su, C.T.; et al. Association of plasma folate, vitamin B12 levels, and arsenic methylation capacity with developmental delay in preschool children in Taiwan. *Arch. Toxicol.* 2019, 93, 2355–2344. [CrossRef]

56. Zhu, J.; Gao, Y.; Sun, D.; Wei, Y. Serum folate and cobalamin levels and urinary dimethylarsinic acid in US children and adults. *Environ. Sci. Pollut. Res. Int.* 2018, 25, 17168–17175. [CrossRef]

57. Skröder Löveborn, H.; Kippler, M.; Lu, Y.; Ahmed, S.; Kuehnelt, D.; Raqib, R.; Vahter, M. Arsenic metabolism in children differs from that in adults. *Toxicol. Sci.* 2016, 152, 29–39. [CrossRef]

58. Zhang, X.; Xu, X.; Zhong, Y.; Power, M.C.; Taylor, B.D.; Carrillo, G. Serum folate levels and urinary arsenic methylation profiles in the US population: NHANES, 2003–2012. *J. Expo. Sci. Environ. Epidemiol.* 2019, 29, 323–334. [CrossRef] [PubMed]

59. Chung, J.S.; Kalman, D.A.; Moore, L.E.; Kosnett, M.J.; Arroyo, A.P.; Beers, M.; Mazumder, D.N.G.; Hernandez, A.L.; Smith, A.H. Family correlations of arsenic methylation patterns in children and parents exposed to high concentrations of arsenic in drinking water. *Environ. Health Perspect.* 2002, 110, 729–733. [CrossRef] [PubMed]

60. Hall, M.N.; Liu, X.; Slavkovich, V.; Ilievski, V.; Mi, Z.; Alam, S.; Factor-Litvak, P.; Ahsan, H.; Graziano, J.H.; Gamble, M.V. Influence of cobalamin on arsenic metabolism in Bangladesh. *Environ. Health Perspect.* 2009, 117, 1724–1729. [CrossRef] [PubMed]

61. Gardner, R.M.; Nermell, B.; Kippler, M.; Grand, D.B.; Herring, A.H.; St, et al. Maternal one carbon metabolism and arsenic methylation in pregnancy in Mexico. *J. Expo. Sci. Environ. Epidemiol.* 2018, 28, 505–514. [CrossRef] [PubMed]

62. Hall, M.N.; Liu, X.; Slavkovich, V.; Ilievski, V.; Mi, Z.; Alam, S.; Factor-Litvak, P.; Ahsan, H.; Graziano, J.H.; Gamble, M.V.; Fry, R.C. Maternal one carbon metabolism and arsenic methylation in a pregnancy cohort in Mexico. *J. Expo. Sci. Environ. Epidemiol.* 2018, 28, 505–514. [CrossRef] [PubMed]

63. Li, L.; Ekström, E.C.; Goessler, W.; Lönnerdal, B.; Nermell, B.; Yunus, M.; Rahman, A.; El Arifeen, S.; Persson, L.A.; Vahter, M. Nutritional status has marginal influence on the metabolism of inorganic arsenic in pregnant Bangladeshi women. *Environ. Health Perspect.* 2008, 116, 315–321. [CrossRef]

64. Gardner, R.M.; Nermell, B.; Kippler, M.; Grandér, M.; Li, L.; Ekström, E.C.; Rahman, A.; Lönnerdal, B.; Hoque, A.M.W.; Vahter, M. Arsenic methylation efficiency increases during the first trimester of pregnancy independent of folate status. *Reprod. Toxicol.* 2011, 31, 210–218. [CrossRef]

65. Hall, M.; Gamble, M.; Slavkovich, V.; Liu, X.; Levy, D.; Cheng, Z.; van Geen, A.; Yunus, M.; Rahman, M.; Pilsnr, J.R.; et al. Determinants of arsenic metabolism: Blood arsenic metabolites, plasma folate, cobalamin, and homocysteine concentrations in maternal-newborn pairs. *Environ. Health Perspect.* 2007, 115, 1503–1509. [PubMed]

66. Niedzwiecki, M.M.; Hall, M.N.; Liu, X.; Slavkovich, V.; Ilievski, V.; Levy, D.; Alam, S.; Siddique, A.B.; Parvez, F.; Graziano, J.H.; et al. Interaction of plasma glutathione redox and folate deficiency on arsenic methylation capacity in Bangladeshi adults. *Free Radic. Biol. Med.* 2014, 73, 67–74. [CrossRef]

67. Chung, C.J.; Pu, Y.S.; Su, C.T.; Chen, H.W.; Huang, Y.K.; Shieue, H.S.; Hsueue, Y.M. Polymorphisms in one-carbon metabolism pathway genes, urinary arsenic profile, and urothelial carcinoma. *Cancer Causes Control* 2010, 21, 1605–1615. [CrossRef]

68. Lambrou, A.; Baccarelli, A.; Wright, R.O.; Weisskopf, M.; Bollati, V.; Amarasiriwardena, C.; Vokonas, P.; Schwartz, J. Arsenic exposure and DNA methylation among elderly men. *Epidemiology* 2012, 23, 668–676. [CrossRef] [PubMed]

69. Pilsnr, J.R.; Liu, X.; Ahsan, H.; Ilievski, V.; Slavkovich, V.; Levy, D.; Factor-Litvak, P.; Graziano, J.H.; Gamble, M.V. Genomic methylation of peripheral blood leukocyte DNA: Influences of arsenic and folate in Bangladeshi adults. *Am. J. Clin. Nutr.* 2007, 86, 1179–1186. [CrossRef] [PubMed]

70. Tauheed, J.; Sanchez-Guerra, M.; Lee, J.J.; Paul, L.; Ibne Hasan, M.O.S.; Quamruzzaman, Q.; Selhub, J.; Wright, R.O.; Christiani, D.C.; Coull, B.A.; et al. Associations between post translational histone modifications, myelomeningocele risk, environmental arsenic exposure, and folate deficiency among participants in a case control study in Bangladesh. *Epinigenetics* 2017, 12, 484–491. [CrossRef]

71. Grau-Pérez, M.; Kuo, C.C.; Spratlen, M.; Thayer, K.A.; Mendez, M.A.; Hamman, R.F.; Dabelea, D.; Adgate, J.L.; Knowler, W.C.; Bell, R.A.; et al. The association of arsenic exposure and metabolism with Type 1 and Type 2 Diabetes in youth: The SEARCH Case-Control Study. *Diabetes Care* 2017, 40, 46–53. [CrossRef]

72. Chung, C.J.; Lee, H.L.; Chang, C.H.; Chang, H.; Liu, C.S.; Jung, W.T.; Liu, H.J.; Liu, S.H.; Chung, M.C.; Hsueue, Y.M. Measurement of urinary arsenic profiles and DNA hypomethylation in a case-control study of urothelial carcinoma. *Arch. Toxicol.* 2019, 93, 2155–2164. [CrossRef] [PubMed]

73. Chung, J.S.; Haque, R.; Guha Mazumder, D.N.; Moore, L.E.; Ghosh, N.; Samanta, S.; Mitra, S.; Hira-Smith, M.M.; von Ehrenstein, O.; Basu, A.; et al. Blood concentrations of methionine, selenium, beta-carotene, and other micronutrients in a case-control study of arsenic-induced skin lesions in West Bengal, India. *Environ. Res.* 2006, 101, 230–237. [CrossRef] [PubMed]

74. Pilsnr, J.R.; Liu, X.; Ahsan, H.; Ilievski, V.; Slavkovich, V.; Levy, D.; Factor-Litvak, P.; Graziano, J.H.; Gamble, M.V. Folate deficiency, hyperhomocysteinemia, low urinary creatinine, and hypomethylation of leukocyte DNA are risk factors for arsenic-induced skin lesions. *Environ. Health Perspect.* 2009, 117, 254–260. [CrossRef]
75. Gong, L.; Yang, Q.; Liu, C.W.B.; Wang, X.; Zeng, H.L. Assessment of 12 essential and toxic elements in whole blood of pregnant and non-pregnant women living in Wuhan of China. *Biol. Trace Elem. Res.* 2020. [CrossRef]

76. Wang, C.T.; Chang, W.T.; Huang, C.W.; Chou, S.S.; Lin, C.T.; Liau, S.J.; Wang, R.T. Studies on the concentrations of arsenic, selenium, copper, zinc and iron in the hair of Blackfoot disease patients in different clinical stages. *Eur. J. Clin. Chem. Clin. Biochem.* 1994, 32, 107–111. [CrossRef]

77. Tsai, J.L.; Horng, P.H.; Hwang, T.J.; Hsu, J.W.; Horng, C.J. Determination of urinary trace elements (arsenic, copper, cadmium, manganese, lead, zinc, selenium) in patients with Blackfoot disease. *Arch. Environ. Health* 2004, 59, 686–692. [CrossRef] [PubMed]

78. Lin, S.M.; Yang, M.H. Arsenic, selenium, and zinc in patients with Blackfoot disease. *Biol. Trace Elem. Res.* 1988, 15, 213–221. [CrossRef] [PubMed]

79. Gerhardsson, L.; Nordberg, G.F. Lung cancer in smelter workers–interactions of metals as indicated by tissue levels. *Scand. J. Work Environ. Health* 1993, 19, 90–94. [PubMed]

80. Tutkun, L.; Gunduzoz, M.; Turksoy, V.A.; Deniz, S.; Oztan, O.; Cetintepe, S.P.; Iritas, S.B.; Yilmaz, F.M. Arsenic-induced inflammation in workers. *Mol. Biol. Rep.* 2019, 46, 2371–2378. [CrossRef] [PubMed]